WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Cancer Vaccines
  • Carcinoma, Non-Small-Cell Lung
  • Mesothelioma
  • Peptide Fragments
  • WT1 Proteins

abstract

  • This multivalent WT1 peptide analog vaccine induces immune responses in a high proportion of patients with thoracic malignancies with minimal toxicity. A randomized trial testing this vaccine as adjuvant therapy in MPM is planned.

publication date

  • October 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4004362

Digital Object Identifier (DOI)

  • 10.1007/s00262-010-0871-8

PubMed ID

  • 20532500

Additional Document Info

start page

  • 1467

end page

  • 79

volume

  • 59

number

  • 10